Key result
The ROADMAP study is designed to evaluate whether olmesartan medoxomil 40 mg daily prevents or delays the onset of microalbuminuria in 4400 patients with type 2 diabetes and normoalbuminuria.
Why the study?
Does olmesartan medoxomil prevent or delay the occurrence of microalbuminuria in type 2 diabetes patients with normoalbuminuria?
Population
4,400 type 2 diabetes patients with normoalbuminuria
Comparison
Olmesartan medoxomil 40 mg once daily vs Placebo
Design
Other, Parallel group randomization, Double-blind
Follow-up
Expected median of 5 years
Authors
Loading...
ROADMAP RCT will test olmesartan for primary prevention of microalbuminuria in normoalbuminuric T2D; leaves open whether ARBs merit early renoprotective use.
RCT (n=4,400)
double-blind
parallel group
Yes
Does olmesartan medoxomil prevent or delay the occurrence of microalbuminuria in type 2 diabetes patients with normoalbuminuria?
The ROADMAP study is designed to evaluate whether the ARB olmesartan can prevent or delay the onset of microalbuminuria in patients with type 2 diabetes.
Haller et al. (2006) conducted an RCT in type 2 diabetes with normoalbuminuria (n=4,400). olmesartan medoxomil vs. placebo was evaluated on occurrence of microalbuminuria. The ROADMAP study is designed to evaluate whether olmesartan medoxomil 40 mg daily prevents or delays the onset of microalbuminuria in 4400 patients with type 2 diabetes and normoalbuminuria.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: